Prevail Therapeutics Inc. Common Stock
PRVL
PRVL was delisted on the 21st of January, 2021.
76 hedge funds and large institutions have $303M invested in Prevail Therapeutics Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 11 closing their positions.
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
13% more funds holding
Funds holding: 67 → 76 (+9)
4.23% more ownership
Funds ownership: 82.62% → 86.85% (+4.2%)
28% less capital invested
Capital invested by funds: $421M → $303M (-$118M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$16.6M |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$15.2M |
| 3 |
BlackRock
New York
|
+$7.5M |
| 4 |
Morgan Stanley
New York
|
+$3.66M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$3.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$15.3M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.77M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.47M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.35M |
| 5 |
Bank of New York Mellon
New York
|
-$914K |
PRVL Hedge Fund Activity: Q3 2020 in Review
76 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q3 2020, worth a combined $303M — down 28% from $421M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PRVL positions and 11 closed out — a net gain of 9 holders — while 23 added to existing stakes and 18 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $16.6M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $15.3M sold.
- 76 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q3 2020, up from 67 in Q2 2020.
- Funds reported $303M of Prevail Therapeutics Inc. Common Stock stock for Q3 2020, down 28% quarter-over-quarter.
- 20 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q3 2020 and 11 closed out, a net change of +9 holders.
- The largest Prevail Therapeutics Inc. Common Stock buyer in Q3 2020 was Citadel Advisors, an estimated $16.6M added.
- The largest Prevail Therapeutics Inc. Common Stock seller in Q3 2020 was Avidity Partners Management, an estimated $15.3M sold.
Based on aggregated 13F filings for Q3 2020.